Concepts (208)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Radiosurgery | 26 | 2020 | 355 | 2.390 |
Why?
|
| Lung Neoplasms | 11 | 2016 | 423 | 1.350 |
Why?
|
| Brain Neoplasms | 14 | 2020 | 637 | 1.230 |
Why?
|
| Neoplasms, Radiation-Induced | 3 | 2012 | 14 | 1.110 |
Why?
|
| Radiation Oncology | 2 | 2016 | 14 | 0.880 |
Why?
|
| Particle Accelerators | 3 | 2016 | 7 | 0.870 |
Why?
|
| Space Flight | 4 | 2019 | 23 | 0.770 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 4 | 2016 | 34 | 0.700 |
Why?
|
| Knee Joint | 3 | 2019 | 128 | 0.690 |
Why?
|
| Magnetic Resonance Imaging | 9 | 2017 | 1223 | 0.690 |
Why?
|
| Cartilage, Articular | 3 | 2019 | 72 | 0.630 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2018 | 907 | 0.560 |
Why?
|
| Weight-Bearing | 1 | 2016 | 42 | 0.490 |
Why?
|
| Arthritis | 1 | 2016 | 30 | 0.480 |
Why?
|
| Trigeminal Neuralgia | 5 | 2019 | 33 | 0.480 |
Why?
|
| Quality Control | 2 | 2016 | 43 | 0.470 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2016 | 36 | 0.470 |
Why?
|
| Quality Assurance, Health Care | 1 | 2016 | 72 | 0.460 |
Why?
|
| Societies, Scientific | 1 | 2013 | 16 | 0.400 |
Why?
|
| Molecular Imaging | 1 | 2013 | 18 | 0.400 |
Why?
|
| Neoplasms | 4 | 2018 | 754 | 0.390 |
Why?
|
| Hindlimb Suspension | 3 | 2019 | 11 | 0.390 |
Why?
|
| Acetylcysteine | 1 | 2012 | 9 | 0.380 |
Why?
|
| Free Radical Scavengers | 1 | 2012 | 14 | 0.380 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2012 | 60 | 0.370 |
Why?
|
| Aged, 80 and over | 22 | 2020 | 3898 | 0.360 |
Why?
|
| Photons | 1 | 2011 | 8 | 0.360 |
Why?
|
| Treatment Outcome | 18 | 2020 | 3416 | 0.360 |
Why?
|
| Retrospective Studies | 20 | 2020 | 3624 | 0.350 |
Why?
|
| Male | 34 | 2020 | 19437 | 0.330 |
Why?
|
| Meningioma | 3 | 2020 | 59 | 0.330 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 5 | 2014 | 108 | 0.330 |
Why?
|
| Middle Aged | 31 | 2020 | 11848 | 0.320 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2011 | 258 | 0.320 |
Why?
|
| Multiple Sclerosis | 3 | 2019 | 62 | 0.320 |
Why?
|
| Aged | 28 | 2020 | 10260 | 0.310 |
Why?
|
| Dose-Response Relationship, Radiation | 10 | 2019 | 83 | 0.310 |
Why?
|
| Female | 32 | 2020 | 19942 | 0.280 |
Why?
|
| Adult | 25 | 2020 | 9256 | 0.280 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2020 | 381 | 0.270 |
Why?
|
| Humans | 37 | 2020 | 32274 | 0.260 |
Why?
|
| Animals | 10 | 2019 | 8199 | 0.250 |
Why?
|
| Salvage Therapy | 4 | 2018 | 135 | 0.250 |
Why?
|
| Mice | 5 | 2019 | 2571 | 0.220 |
Why?
|
| Facial Pain | 3 | 2012 | 21 | 0.220 |
Why?
|
| Whole-Body Irradiation | 2 | 2015 | 58 | 0.210 |
Why?
|
| Follow-Up Studies | 12 | 2018 | 2240 | 0.200 |
Why?
|
| Radiotherapy Dosage | 9 | 2016 | 107 | 0.200 |
Why?
|
| Radiation Injuries | 4 | 2016 | 85 | 0.190 |
Why?
|
| Models, Statistical | 3 | 2016 | 187 | 0.170 |
Why?
|
| Carcinoma | 1 | 2020 | 92 | 0.150 |
Why?
|
| Rats | 4 | 2016 | 1895 | 0.150 |
Why?
|
| Trigeminal Nerve | 2 | 2010 | 5 | 0.150 |
Why?
|
| Radiometry | 3 | 2015 | 52 | 0.150 |
Why?
|
| Phantoms, Imaging | 3 | 2015 | 70 | 0.150 |
Why?
|
| Hip Joint | 1 | 2019 | 67 | 0.140 |
Why?
|
| Tumor Burden | 3 | 2014 | 63 | 0.130 |
Why?
|
| Neoplasm Metastasis | 1 | 2018 | 222 | 0.130 |
Why?
|
| Young Adult | 6 | 2020 | 2648 | 0.130 |
Why?
|
| Nervous System Neoplasms | 1 | 2017 | 8 | 0.130 |
Why?
|
| Anus Neoplasms | 1 | 2016 | 13 | 0.120 |
Why?
|
| Femur Neck | 1 | 2016 | 18 | 0.120 |
Why?
|
| Time Factors | 5 | 2019 | 2204 | 0.120 |
Why?
|
| Glycosaminoglycans | 1 | 2016 | 23 | 0.120 |
Why?
|
| Maintenance | 1 | 2016 | 2 | 0.120 |
Why?
|
| Melanoma | 1 | 2017 | 166 | 0.120 |
Why?
|
| Tibia | 1 | 2016 | 56 | 0.120 |
Why?
|
| Femur | 1 | 2016 | 75 | 0.120 |
Why?
|
| Pelvis | 1 | 2016 | 67 | 0.120 |
Why?
|
| Equipment Failure | 1 | 2016 | 25 | 0.120 |
Why?
|
| Survival Rate | 6 | 2018 | 893 | 0.120 |
Why?
|
| Survival Analysis | 5 | 2020 | 477 | 0.120 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2018 | 189 | 0.120 |
Why?
|
| Radiation Dosage | 4 | 2020 | 91 | 0.120 |
Why?
|
| Intracranial Arteriovenous Malformations | 2 | 2012 | 19 | 0.110 |
Why?
|
| Ribs | 1 | 2016 | 44 | 0.110 |
Why?
|
| Weightlessness | 1 | 2015 | 9 | 0.110 |
Why?
|
| Radiation, Ionizing | 1 | 2015 | 21 | 0.110 |
Why?
|
| Software | 1 | 2016 | 124 | 0.110 |
Why?
|
| Collagen | 1 | 2016 | 229 | 0.110 |
Why?
|
| Cosmic Radiation | 1 | 2014 | 10 | 0.110 |
Why?
|
| Body Weight | 1 | 2016 | 323 | 0.110 |
Why?
|
| Joints | 1 | 2014 | 12 | 0.110 |
Why?
|
| Mediastinal Neoplasms | 1 | 2014 | 15 | 0.100 |
Why?
|
| Brain Stem Neoplasms | 1 | 2014 | 4 | 0.100 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2016 | 897 | 0.100 |
Why?
|
| Oxygen | 1 | 2014 | 138 | 0.100 |
Why?
|
| Thorax | 1 | 2014 | 32 | 0.100 |
Why?
|
| Disease-Free Survival | 4 | 2020 | 324 | 0.100 |
Why?
|
| Pulmonary Alveoli | 1 | 2013 | 20 | 0.100 |
Why?
|
| Epithelium | 1 | 2013 | 22 | 0.100 |
Why?
|
| Mice, Inbred A | 1 | 2012 | 5 | 0.100 |
Why?
|
| Nitrosamines | 1 | 2012 | 6 | 0.100 |
Why?
|
| Carcinogens | 1 | 2012 | 36 | 0.090 |
Why?
|
| Lung Injury | 1 | 2013 | 67 | 0.090 |
Why?
|
| Neurilemmoma | 1 | 2012 | 17 | 0.090 |
Why?
|
| Mice, Inbred BALB C | 1 | 2012 | 196 | 0.090 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2012 | 17 | 0.090 |
Why?
|
| Whole Body Imaging | 1 | 2011 | 6 | 0.090 |
Why?
|
| Cognition Disorders | 1 | 2014 | 349 | 0.090 |
Why?
|
| Meningeal Neoplasms | 1 | 2012 | 49 | 0.090 |
Why?
|
| Disease Susceptibility | 1 | 2011 | 61 | 0.090 |
Why?
|
| Collagen Diseases | 1 | 2011 | 5 | 0.090 |
Why?
|
| Treatment Failure | 3 | 2020 | 165 | 0.080 |
Why?
|
| Prognosis | 4 | 2018 | 1534 | 0.080 |
Why?
|
| Hypesthesia | 1 | 2010 | 9 | 0.080 |
Why?
|
| Radiotherapy, Conformal | 2 | 2008 | 18 | 0.080 |
Why?
|
| Vascular Diseases | 1 | 2011 | 66 | 0.080 |
Why?
|
| Cone-Beam Computed Tomography | 1 | 2010 | 21 | 0.080 |
Why?
|
| Disease Progression | 1 | 2012 | 591 | 0.080 |
Why?
|
| Brachytherapy | 1 | 2010 | 31 | 0.080 |
Why?
|
| Medical Records | 1 | 2010 | 75 | 0.080 |
Why?
|
| Chi-Square Distribution | 1 | 2010 | 287 | 0.080 |
Why?
|
| Analysis of Variance | 1 | 2010 | 471 | 0.080 |
Why?
|
| Cranial Irradiation | 3 | 2017 | 94 | 0.070 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2010 | 232 | 0.070 |
Why?
|
| Prospective Studies | 5 | 2019 | 2316 | 0.070 |
Why?
|
| Neurofibromatoses | 1 | 2008 | 2 | 0.070 |
Why?
|
| Thoracic Neoplasms | 1 | 2008 | 6 | 0.070 |
Why?
|
| Smoking | 1 | 2011 | 505 | 0.070 |
Why?
|
| Child | 4 | 2020 | 2434 | 0.070 |
Why?
|
| Databases, Factual | 2 | 2020 | 368 | 0.060 |
Why?
|
| X-Ray Microtomography | 2 | 2019 | 45 | 0.060 |
Why?
|
| Cobalt Radioisotopes | 1 | 2006 | 3 | 0.060 |
Why?
|
| Postoperative Complications | 1 | 2012 | 823 | 0.060 |
Why?
|
| Incidence | 2 | 2020 | 1241 | 0.060 |
Why?
|
| Multivariate Analysis | 3 | 2013 | 651 | 0.060 |
Why?
|
| Bone Density | 2 | 2018 | 169 | 0.060 |
Why?
|
| Tomography, Spiral Computed | 1 | 2005 | 19 | 0.060 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2008 | 443 | 0.050 |
Why?
|
| Adolescent | 4 | 2020 | 3517 | 0.050 |
Why?
|
| Pain Measurement | 3 | 2012 | 341 | 0.050 |
Why?
|
| Rats, Inbred F344 | 2 | 2014 | 151 | 0.050 |
Why?
|
| Brain | 1 | 2010 | 965 | 0.050 |
Why?
|
| Retreatment | 2 | 2016 | 42 | 0.050 |
Why?
|
| Radiotherapy, High-Energy | 1 | 2003 | 4 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2019 | 1840 | 0.050 |
Why?
|
| Transforming Growth Factor beta | 1 | 2003 | 63 | 0.050 |
Why?
|
| Radiation Pneumonitis | 1 | 2002 | 4 | 0.050 |
Why?
|
| ROC Curve | 1 | 2002 | 169 | 0.050 |
Why?
|
| Child, Preschool | 2 | 2020 | 1233 | 0.040 |
Why?
|
| Logistic Models | 2 | 2016 | 743 | 0.040 |
Why?
|
| Lung | 1 | 2002 | 263 | 0.040 |
Why?
|
| Neoplasm Staging | 2 | 2014 | 461 | 0.040 |
Why?
|
| Combined Modality Therapy | 2 | 2014 | 555 | 0.040 |
Why?
|
| Transforming Growth Factor beta1 | 2 | 2013 | 25 | 0.040 |
Why?
|
| Thoracic Vertebrae | 1 | 2018 | 39 | 0.030 |
Why?
|
| Organ Size | 1 | 2018 | 221 | 0.030 |
Why?
|
| Lumbar Vertebrae | 1 | 2018 | 97 | 0.030 |
Why?
|
| North Carolina | 2 | 2013 | 1300 | 0.030 |
Why?
|
| Hearing Tests | 1 | 2017 | 12 | 0.030 |
Why?
|
| Macaca mulatta | 1 | 2018 | 340 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2019 | 792 | 0.030 |
Why?
|
| Probability | 1 | 2016 | 155 | 0.030 |
Why?
|
| Rib Fractures | 1 | 2016 | 21 | 0.030 |
Why?
|
| Environmental Exposure | 1 | 2015 | 60 | 0.030 |
Why?
|
| Rats, Inbred BN | 1 | 2014 | 31 | 0.030 |
Why?
|
| Respiration | 1 | 2014 | 29 | 0.030 |
Why?
|
| Nanotechnology | 1 | 2014 | 18 | 0.030 |
Why?
|
| Lower Extremity | 1 | 2015 | 100 | 0.030 |
Why?
|
| Brain Stem | 1 | 2014 | 22 | 0.030 |
Why?
|
| Bone and Bones | 1 | 2014 | 91 | 0.030 |
Why?
|
| Osteoarthritis | 1 | 2014 | 73 | 0.030 |
Why?
|
| Aquaporin 5 | 1 | 2013 | 4 | 0.020 |
Why?
|
| Pulmonary Surfactant-Associated Protein C | 1 | 2013 | 2 | 0.020 |
Why?
|
| Cause of Death | 1 | 2014 | 236 | 0.020 |
Why?
|
| Vimentin | 1 | 2013 | 10 | 0.020 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2013 | 17 | 0.020 |
Why?
|
| Mice, Inbred Strains | 1 | 2013 | 55 | 0.020 |
Why?
|
| Cadherins | 1 | 2013 | 28 | 0.020 |
Why?
|
| Gamma Rays | 1 | 2013 | 25 | 0.020 |
Why?
|
| Protein Transport | 1 | 2013 | 80 | 0.020 |
Why?
|
| Spin Labels | 1 | 2012 | 17 | 0.020 |
Why?
|
| Cerebral Angiography | 1 | 2012 | 60 | 0.020 |
Why?
|
| Cell Line | 1 | 2013 | 454 | 0.020 |
Why?
|
| Facial Paralysis | 1 | 2011 | 6 | 0.020 |
Why?
|
| Hydrocephalus | 1 | 2011 | 11 | 0.020 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2011 | 36 | 0.020 |
Why?
|
| Pons | 1 | 2010 | 7 | 0.020 |
Why?
|
| Spinal Nerve Roots | 1 | 2010 | 12 | 0.020 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2010 | 86 | 0.020 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2011 | 149 | 0.020 |
Why?
|
| Glioma | 1 | 2011 | 137 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2012 | 773 | 0.020 |
Why?
|
| Recurrence | 1 | 2010 | 285 | 0.020 |
Why?
|
| Prevalence | 1 | 2012 | 955 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2012 | 883 | 0.020 |
Why?
|
| Placebos | 1 | 2008 | 68 | 0.020 |
Why?
|
| Maximum Tolerated Dose | 1 | 2008 | 62 | 0.020 |
Why?
|
| Remission Induction | 1 | 2008 | 92 | 0.020 |
Why?
|
| Carboplatin | 1 | 2008 | 42 | 0.020 |
Why?
|
| Deoxycytidine | 1 | 2008 | 57 | 0.020 |
Why?
|
| Paclitaxel | 1 | 2008 | 57 | 0.020 |
Why?
|
| Algorithms | 1 | 2010 | 536 | 0.020 |
Why?
|
| Radiography | 1 | 2008 | 362 | 0.020 |
Why?
|
| Radioactivity | 1 | 2006 | 2 | 0.020 |
Why?
|
| Half-Life | 1 | 2006 | 24 | 0.020 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2008 | 157 | 0.020 |
Why?
|
| Scattering, Radiation | 1 | 2005 | 19 | 0.010 |
Why?
|
| Biophysics | 1 | 2005 | 13 | 0.010 |
Why?
|
| Biophysical Phenomena | 1 | 2005 | 10 | 0.010 |
Why?
|
| Rotation | 1 | 2005 | 51 | 0.010 |
Why?
|
| Adenocarcinoma | 1 | 2008 | 297 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2005 | 556 | 0.010 |
Why?
|
| Risk Factors | 1 | 2012 | 3934 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2002 | 273 | 0.010 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2002 | 20 | 0.010 |
Why?
|
| Linear Models | 1 | 2002 | 425 | 0.010 |
Why?
|